SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rooney, C. M. Articles by Heslop, H. E. Search for Related Content PubMed PubMed Citation Articles by Rooney, C. M. Articles by Heslop, H. E. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 92 No. 5 (September 1), 1998: pp. 1549-1555 Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus-Induced Lymphoma in Allogeneic Transplant Recipients Cliona M. Rooney, Colton A. Smith, Catherine Y.C. Ng, Susan K. Loftin, John W. Sixbey, Yanjun Gan, Deo-Kumar Srivastava, Laura C. Bowman, Robert A. Krance, Malcolm K. Brenner, and Helen E. Heslop From the Departments of Virology and Molecular Biology, Biostatistics, and the Division of Bone Marrow Transplantation, St Jude Children's Research Hospital, Memphis, TN; and the Departments of Pathology and Pediatrics, University of Tennessee, Memphis, TN. Epstein-Barr virus (EBV) causes potentially lethal immunoblastic lymphoma in up to 25% of children receiving bone marrow transplants from unrelated or HLA-mismatched donors. Because this complication appears to stem from a deficiency of EBV-specific cytotoxic T cells, we assessed the safety and efficacy of donor-derived polyclonal (CD4+ and CD8+) T-cell lines as immunoprophylaxis and treatment for EBV-related lymphoma. Thirty-nine patients considered to be at high risk for EBV-induced lymphoma each received 2 to 4 intravenous infusions of donor-derived EBV-specific T lymphocytes, after they had received T-cell-depleted bone marrow from HLA-matched unrelated donors (n = 33) or mismatched family members (n = 6). The immunologic effects of this therapy were monitored during and after the infusions. Infused cells were identified by detection of the neo marker gene. EBV-specific T cells bearing the neo marker were identified in all but 1 of the patients. Serial analysis of DNA detected the marker gene for as long as 18 weeks in unmanipulated peripheral blood mononuclear cells and for as long as 38 months in regenerated lines of EBV-specific cytotoxic T cells. Six patients (15.5%) had greatly increased amounts of EBV-DNA on study entry (>2,000 genome copies/106 mononuclear cells), indicating uncontrolled EBV replication, a complication that has had a high correlation with subsequent development of overt lymphoma. All of these patients showed 2 to 4 log decreases in viral DNA levels within 2 to 3 weeks after infusion and none developed lymphoma, confirming the antiviral activity of the donor-derived cells. There were no toxic effects that could be attributed to prophylactic T-cell therapy. Two additional patients who did not receive prophylaxis and developed overt immunoblastic lymphoma responded fully to T-cell infusion. Polyclonal donor-derived T-cell lines specific for EBV proteins can thus be used safely to prevent EBV-related immunoblastic lymphoma after allogeneic marrow transplantation and may also be effective in the treatment of established disease. © 1998 by The American Society of Hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. E. Heslop How I treat EBV lymphoproliferation Blood, November 5, 2009; 114(19): 4002 - 4008. [Abstract] [Full Text] [PDF] S. Singh, P. van Hauten, K. Jones, K. Grimmett, A. K. Mills, and M. K. Gandhi Selective accumulation of virus-specific CD8+ T cells within the peripheral blood stem cell compartment Blood, August 27, 2009; 114(9): 2001 - 2003. [Full Text] [PDF] A. N. Hasan, W. J. Kollen, D. Trivedi, A. Selvakumar, B. Dupont, M. Sadelain, and R. J. O'Reilly A Panel of Artificial APCs Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Dominant and Subdominant Viral Epitopes for Adoptive Therapy J. Immunol., August 15, 2009; 183(4): 2837 - 2850. [Abstract] [Full Text] [PDF] H. M. Long, J. Zuo, A. M. Leese, N. H. Gudgeon, H. Jia, G. S. Taylor, and A. B. Rickinson CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells Blood, July 23, 2009; 114(4): 807 - 815. [Abstract] [Full Text] [PDF] K. A. McAulay, T. Haque, G. Urquhart, C. Bellamy, D. Guiretti, and D. H. Crawford Epitope Specificity and Clonality of EBV-Specific CTLs Used to Treat Posttransplant Lymphoproliferative Disease J. Immunol., March 15, 2009; 182(6): 3892 - 3901. [Abstract] [Full Text] [PDF] C. U. Louis, K. Straathof, C. M. Bollard, C. Gerken, M. H. Huls, M. V. Gresik, M.-F. Wu, H. L. Weiss, A. P. Gee, M. K. Brenner, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients Blood, March 12, 2009; 113(11): 2442 - 2450. [Abstract] [Full Text] [PDF] J. M. Brooks, S. P. Lee, A. M. Leese, W. A. Thomas, M. Rowe, and A. B. Rickinson Cyclical Expression of EBV Latent Membrane Protein 1 in EBV-Transformed B Cells Underpins Heterogeneity of Epitope Presentation and CD8+ T Cell Recognition J. Immunol., February 15, 2009; 182(4): 1919 - 1928. [Abstract] [Full Text] [PDF] A. Joshi, J. Tang, M. Kuzma, J. Wagner, B. Mookerjee, J. Filicko, M. Carabasi, N. Flomenberg, and P. Flomenberg Adenovirus DNA polymerase is recognized by human CD8+ T cells J. Gen. Virol., January 1, 2009; 90(1): 84 - 94. [Abstract] [Full Text] [PDF] M. E. Dudley and S. A. Rosenberg Clinical Trials Investigating Adoptive Cell Therapy Combined with Lymphodepletion for Patients with Advanced Cancer ASCO Educational Book, January 1, 2009; 2009(1): 516 - 520. [Abstract] [Full Text] [PDF] T. Ando, K. Mimura, C. C. Johansson, M. G. Hanson, D. Mougiakakos, C. Larsson, T. Martins da Palma, D. Sakurai, H. Norell, M. Li, et al. Transduction with the Antioxidant Enzyme Catalase Protects Human T Cells against Oxidative Stress J. Immunol., December 15, 2008; 181(12): 8382 - 8390. [Abstract] [Full Text] [PDF] K. P. Micklethwaite, L. Clancy, U. Sandher, A. M. Hansen, E. Blyth, V. Antonenas, M. M. Sartor, K. F. Bradstock, and D. J. Gottlieb Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation Blood, November 15, 2008; 112(10): 3974 - 3981. [Abstract] [Full Text] [PDF] J. King, J. Waxman, and H. Stauss Advances in tumour immunotherapy QJM, September 1, 2008; 101(9): 675 - 683. [Abstract] [Full Text] [PDF] C. Quintarelli, G. Dotti, B. De Angelis, V. Hoyos, M. Mims, L. Luciano, H. E. Heslop, C. M. Rooney, F. Pane, and B. Savoldo Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia Blood, September 1, 2008; 112(5): 1876 - 1885. [Abstract] [Full Text] [PDF] A. Carbone, A. Gloghini, and G. Dotti EBV-Associated Lymphoproliferative Disorders: Classification and Treatment Oncologist, May 1, 2008; 13(5): 577 - 585. [Abstract] [Full Text] [PDF] H. Singh, P. R. Manuri, S. Olivares, N. Dara, M. J. Dawson, H. Huls, P. B. Hackett, D. B. Kohn, E. J. Shpall, R. E. Champlin, et al. Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System Cancer Res., April 15, 2008; 68(8): 2961 - 2971. [Abstract] [Full Text] [PDF] D. Adhikary, U. Behrends, R. Feederle, H.-J. Delecluse, and J. Mautner Standardized and Highly Efficient Expansion of Epstein-Barr Virus-Specific CD4+ T Cells by Using Virus-Like Particles J. Virol., April 15, 2008; 82(8): 3903 - 3911. [Abstract] [Full Text] [PDF] H. Kobayashi, T. Nagato, M. Takahara, K. Sato, S. Kimura, N. Aoki, M. Azumi, M. Tateno, Y. Harabuchi, and E. Celis Induction of EBV-Latent Membrane Protein 1-Specific MHC Class II-Restricted T-Cell Responses against Natural Killer Lymphoma Cells Cancer Res., February 1, 2008; 68(3): 901 - 908. [Abstract] [Full Text] [PDF] T. A. Haigh, X. Lin, H. Jia, E. P. Hui, A. T. C. Chan, A. B. Rickinson, and G. S. Taylor EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+ Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines J. Immunol., February 1, 2008; 180(3): 1643 - 1654. [Abstract] [Full Text] [PDF] N. A. Bakker and G. W. van Imhoff Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention? Haematologica, November 1, 2007; 92(11): 1447 - 1450. [Full Text] [PDF] A. U. van Lent, M. Nagasawa, M. M. van Loenen, R. Schotte, T. N. M. Schumacher, M. H. M. Heemskerk, H. Spits, and N. Legrand Functional Human Antigen-Specific T Cells Produced In Vitro Using Retroviral T Cell Receptor Transfer into Hematopoietic Progenitors J. Immunol., October 15, 2007; 179(8): 4959 - 4968. [Abstract] [Full Text] [PDF] C. M. Bollard, S. Gottschalk, A. M. Leen, H. Weiss, K. C. Straathof, G. Carrum, M. Khalil, M.-f. Wu, M. H. Huls, C.-C. Chang, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer Blood, October 15, 2007; 110(8): 2838 - 2845. [Abstract] [Full Text] [PDF] C. Quintarelli, J. F. Vera, B. Savoldo, G. M. P. Giordano Attianese, M. Pule, A. E. Foster, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes Blood, October 15, 2007; 110(8): 2793 - 2802. [Abstract] [Full Text] [PDF] B. Savoldo, C. M. Rooney, A. Di Stasi, H. Abken, A. Hombach, A. E. Foster, L. Zhang, H. E. Heslop, M. K. Brenner, and G. Dotti Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30{zeta} artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease Blood, October 1, 2007; 110(7): 2620 - 2630. [Abstract] [Full Text] [PDF] J. M. Cohen, N. J. Sebire, J. Harvey, H. B. Gaspar, C. Cathy, A. Jones, K. Rao, D. Cubitt, P. J. Amrolia, E. G. Davies, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation Blood, September 15, 2007; 110(6): 2209 - 2214. [Abstract] [Full Text] [PDF] L. J. Swinnen EBV-specific T-cell therapy Blood, August 15, 2007; 110(4): 1087 - 1088. [Full Text] [PDF] T. Haque, G. M. Wilkie, M. M. Jones, C. D. Higgins, G. Urquhart, P. Wingate, D. Burns, K. McAulay, M. Turner, C. Bellamy, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial Blood, August 15, 2007; 110(4): 1123 - 1131. [Abstract] [Full Text] [PDF] C. Traversari, S. Marktel, Z. Magnani, P. Mangia, V. Russo, F. Ciceri, C. Bonini, and C. Bordignon The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies Blood, June 1, 2007; 109(11): 4708 - 4715. [Abstract] [Full Text] [PDF] M. O. Butler, J.-S. Lee, S. Ansen, D. Neuberg, F. S. Hodi, A. P. Murray, L. Drury, A. Berezovskaya, R. C. Mulligan, L. M. Nadler, et al. Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell Clin. Cancer Res., March 15, 2007; 13(6): 1857 - 1867. [Abstract] [Full Text] [PDF] E. Biagi, V. Marin, G. M. P. Giordano Attianese, E. Dander, G. D'Amico, and A. Biondi Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies Haematologica, March 1, 2007; 92(3): 381 - 388. [Abstract] [Full Text] [PDF] O. Stuve, C. M. Marra, P. D. Cravens, M. P. Singh, W. Hu, A. Lovett-Racke, N. L. Monson, J. T. Phillips, J. W. C. Tervaert, R. A. Nash, et al. Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions Arch Neurol, February 1, 2007; 64(2): 169 - 176. [Abstract] [Full Text] [PDF] T. C. Wehler, M. Nonn, B. Brandt, C. M. Britten, M. Grone, M. Todorova, I. Link, S. A. Khan, R. G. Meyer, C. Huber, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines Blood, January 1, 2007; 109(1): 365 - 373. [Abstract] [Full Text] [PDF] S. Kausche, T. Wehler, E. Schnurer, V. Lennerz, W. Brenner, S. Melchior, M. Grone, M. Nonn, S. Strand, R. Meyer, et al. Superior Antitumor In vitro Responses of Allogeneic Matched Sibling Compared with Autologous Patient CD8+ T Cells Cancer Res., December 1, 2006; 66(23): 11447 - 11454. [Abstract] [Full Text] [PDF] B. Savoldo, J. A. Goss, M. M. Hammer, L. Zhang, T. Lopez, A. P. Gee, Y.-F. Lin, R. E. Quiros-Tejeira, P. Reinke, S. Schubert, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs) Blood, November 1, 2006; 108(9): 2942 - 2949. [Abstract] [Full Text] [PDF] C. G. Brunstein, D. J. Weisdorf, T. DeFor, J. N. Barker, J. Tolar, J.-A. H. van Burik, and J. E. Wagner Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation Blood, October 15, 2006; 108(8): 2874 - 2880. [Abstract] [Full Text] [PDF] G. S. Taylor, H. M. Long, T. A. Haigh, M. Larsen, J. Brooks, and A. B. Rickinson A Role for Intercellular Antigen Transfer in the Recognition of EBV-Transformed B Cell Lines by EBV Nuclear Antigen-Specific CD4+ T Cells J. Immunol., September 15, 2006; 177(6): 3746 - 3756. [Abstract] [Full Text] [PDF] P. J. Amrolia, G. Muccioli-Casadei, H. Huls, S. Adams, A. Durett, A. Gee, E. Yvon, H. Weiss, M. Cobbold, H. B. Gaspar, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation Blood, September 15, 2006; 108(6): 1797 - 1808. [Abstract] [Full Text] [PDF] R. A. Willemsen, Z. Sebestyen, C. Ronteltap, C. Berrevoets, J. Drexhage, and R. Debets CD8{alpha} Coreceptor to Improve TCR Gene Transfer to Treat Melanoma: Down-Regulation of Tumor-Specific Production of IL-4, IL-5, and IL-10 J. Immunol., July 15, 2006; 177(2): 991 - 998. [Abstract] [Full Text] [PDF] B. Clemenceau, N. Congy-Jolivet, G. Gallot, R. Vivien, J. Gaschet, G. Thibault, and H. Vie Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes Blood, June 15, 2006; 107(12): 4669 - 4677. [Abstract] [Full Text] [PDF] S. Choquet, V. Leblond, R. Herbrecht, G. Socie, A.-M. Stoppa, P. Vandenberghe, A. Fischer, F. Morschhauser, G. Salles, W. Feremans, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study Blood, April 15, 2006; 107(8): 3053 - 3057. [Abstract] [Full Text] [PDF] M. H. Fogg, D. Garry, A. Awad, F. Wang, and A. Kaur The BZLF1 Homolog of an Epstein-Barr-Related {gamma}-Herpesvirus Is a Frequent Target of the CTL Response in Persistently Infected Rhesus Macaques J. Immunol., March 15, 2006; 176(6): 3391 - 3401. [Abstract] [Full Text] [PDF] A. Bondanza, V. Valtolina, Z. Magnani, M. Ponzoni, K. Fleischhauer, M. Bonyhadi, C. Traversari, F. Sanvito, S. Toma, M. Radrizzani, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes Blood, March 1, 2006; 107(5): 1828 - 1836. [Abstract] [Full Text] [PDF] C. Le Clorennec, I. Youlyouz-Marfak, E. Adriaenssens, J. Coll, G. W. Bornkamm, and J. Feuillard EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-{kappa}B, STAT1, and p53 Blood, March 1, 2006; 107(5): 2070 - 2078. [Abstract] [Full Text] [PDF] K. Perruccio, A. Tosti, E. Burchielli, F. Topini, L. Ruggeri, A. Carotti, M. Capanni, E. Urbani, A. Mancusi, F. Aversa, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation Blood, December 15, 2005; 106(13): 4397 - 4406. [Abstract] [Full Text] [PDF] M. H. Fogg, A. Kaur, Y.-G. Cho, and F. Wang The CD8+ T-Cell Response to an Epstein-Barr Virus-Related Gammaherpesvirus Infecting Rhesus Macaques Provides Evidence for Immune Evasion by the EBNA-1 Homologue J. Virol., October 15, 2005; 79(20): 12681 - 12691. [Abstract] [Full Text] [PDF] K. C. Straathof, A. M. Leen, E. L. Buza, G. Taylor, M. H. Huls, H. E. Heslop, C. M. Rooney, and C. M. Bollard Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma J. Immunol., September 15, 2005; 175(6): 4137 - 4147. [Abstract] [Full Text] [PDF] W. N. Haining, D. S. Neuberg, H. L. Keczkemethy, J. W. Evans, S. Rivoli, R. Gelman, H. M. Rosenblatt, W. T. Shearer, J. Guenaga, D. C. Douek, et al. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia Blood, September 1, 2005; 106(5): 1749 - 1754. [Abstract] [Full Text] [PDF] A. Claviez, M. Tiemann, H. Luders, M. Krams, R. Parwaresch, G. Schellong, and W. Dorffel Impact of Latent Epstein-Barr Virus Infection on Outcome in Children and Adolescents With Hodgkin's Lymphoma J. Clin. Oncol., June 20, 2005; 23(18): 4048 - 4056. [Abstract] [Full Text] [PDF] G. Dotti, B. Savoldo, M. Pule, K. C. Straathof, E. Biagi, E. Yvon, S. Vigouroux, M. K. Brenner, and C. M. Rooney Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis Blood, June 15, 2005; 105(12): 4677 - 4684. [Abstract] [Full Text] [PDF] K. C. Straathof, M. A. Pule, P. Yotnda, G. Dotti, E. F. Vanin, M. K. Brenner, H. E. Heslop, D. M. Spencer, and C. M. Rooney An inducible caspase 9 safety switch for T-cell therapy Blood, June 1, 2005; 105(11): 4247 - 4254. [Abstract] [Full Text] [PDF] E. C. Morris, A. Tsallios, G. M. Bendle, S.-a. Xue, and H. J. Stauss A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection PNAS, May 31, 2005; 102(22): 7934 - 7939. [Abstract] [Full Text] [PDF] K. Noonan, W. Matsui, P. Serafini, R. Carbley, G. Tan, J. Khalili, M. Bonyhadi, H. Levitsky, K. Whartenby, and I. Borrello Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors Cancer Res., March 1, 2005; 65(5): 2026 - 2034. [Abstract] [Full Text] [PDF] K. C. M. Straathof, C. M. Bollard, U. Popat, M. H. Huls, T. Lopez, M. C. Morriss, M. V. Gresik, A. P. Gee, H. V. Russell, M. K. Brenner, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes Blood, March 1, 2005; 105(5): 1898 - 1904. [Abstract] [Full Text] [PDF] J. E. Dierksheide, R. A. Baiocchi, A. K. Ferketich, S. Roychowdhury, R. P. Pelletier, C. F. Eisenbeis, M. A. Caligiuri, and A. M. VanBuskirk IFN-{gamma} gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice Blood, February 15, 2005; 105(4): 1558 - 1565. [Abstract] [Full Text] [PDF] H. E. Heslop Biology and Treatment of Epstein-Barr Virus-Associated Non-Hodgkin Lymphomas Hematology, January 1, 2005; 2005(1): 260 - 266. [Abstract] [Full Text] [PDF] S. R. Riddell Finding a Place for Tumor-specific T Cells in Targeted Cancer Therapy J. Exp. Med., December 20, 2004; 200(12): 1533 - 1537. [Abstract] [Full Text] [PDF] C. M. Bollard, L. Aguilar, K. C. Straathof, B. Gahn, M. H. Huls, A. Rousseau, J. Sixbey, M. V. Gresik, G. Carrum, M. Hudson, et al. Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease J. Exp. Med., December 20, 2004; 200(12): 1623 - 1633. [Abstract] [Full Text] [PDF] M. Islas-Ohlmayer, A. Padgett-Thomas, R. Domiati-Saad, M. W. Melkus, P. D. Cravens, M. d. P. Martin, G. Netto, and J. V. Garcia Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34+ Cells with Epstein-Barr Virus J. Virol., December 15, 2004; 78(24): 13891 - 13900. [Abstract] [Full Text] [PDF] P. Yotnda, B. Savoldo, N. Charlet-Berguerand, C. Rooney, and M. Brenner Targeted delivery of adenoviral vectors by cytotoxic T cells Blood, October 15, 2004; 104(8): 2272 - 2280. [Abstract] [Full Text] [PDF] Z. Wang, C. La Rosa, S. Mekhoubad, S. F. Lacey, M. C. Villacres, S. Markel, J. Longmate, J. D. I. Ellenhorn, R. F. Siliciano, C. Buck, et al. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells Blood, August 1, 2004; 104(3): 847 - 856. [Abstract] [Full Text] [PDF] J. N. Blattman and P. D. Greenberg Cancer Immunotherapy: A Treatment for the Masses Science, July 9, 2004; 305(5681): 200 - 205. [Abstract] [Full Text] [PDF] J. E. Davis, M. A. Sherritt, M. Bharadwaj, L. E. Morrison, S. L. Elliott, L. M. Kear, J. Maddicks-Law, T. Kotsimbos, D. Gill, M. Malouf, et al. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD Int. Immunol., July 1, 2004; 16(7): 983 - 989. [Abstract] [Full Text] [PDF] H.-J. Wagner, Y. C. Cheng, M. H. Huls, A. P. Gee, I. Kuehnle, R. A. Krance, M. K. Brenner, C. M. Rooney, and H. E. Heslop Prompt versus preemptive intervention for EBV lymphoproliferative disease Blood, May 15, 2004; 103(10): 3979 - 3981. [Abstract] [Full Text] [PDF] A. T.C. Chan, Q. Tao, K. D. Robertson, I. W. Flinn, R. B. Mann, B. Klencke, W. H. Kwan, T. W.-T. Leung, P. J. Johnson, and R. F. Ambinder Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors J. Clin. Oncol., April 15, 2004; 22(8): 1373 - 1381. [Abstract] [Full Text] [PDF] G. S. Taylor, T. A. Haigh, N. H. Gudgeon, R. J. Phelps, S. P. Lee, N. M. Steven, and A. B. Rickinson Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma J. Virol., January 15, 2004; 78(2): 768 - 778. [Abstract] [Full Text] [PDF] E. B. Walker, D. Haley, W. Miller, K. Floyd, K. P. Wisner, N. Sanjuan, H. Maecker, P. Romero, H.-M. Hu, W. G. Alvord, et al. gp100209-2M Peptide Immunization of Human Lymphocyte Antigen-A2+ Stage I-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8+ T Cells Clin. Cancer Res., January 15, 2004; 10(2): 668 - 680. [Abstract] [Full Text] [PDF] I. Kang, T. Quan, H. Nolasco, S.-H. Park, M. S. Hong, J. Crouch, E. G. Pamer, J. G. Howe, and J. Craft Defective Control of Latent Epstein-Barr Virus Infection in Systemic Lupus Erythematosus J. Immunol., January 15, 2004; 172(2): 1287 - 1294. [Abstract] [Full Text] [PDF] P. Comoli, R. De Palma, S. Siena, A. Nocera, S. Basso, F. Del Galdo, R. Schiavo, O. Carminati, A. Tagliamacco, G. F. Abbate, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma Ann. Onc., January 1, 2004; 15(1): 113 - 117. [Abstract] [Full Text] [PDF] S. Vigouroux, E. Yvon, H.-J. Wagner, E. Biagi, G. Dotti, U. Sili, C. Lira, C. M. Rooney, and M. K. Brenner Induction of Antigen-Specific Regulatory T Cells following Overexpression of a Notch Ligand by Human B Lymphocytes J. Virol., October 15, 2003; 77(20): 10872 - 10880. [Abstract] [Full Text] [PDF] P. Andreone, A. Gramenzi, S. Lorenzini, M. Biselli, C. Cursaro, S. Pileri, and M. Bernardi Posttransplantation Lymphoproliferative Disorders Arch Intern Med, September 22, 2003; 163(17): 1997 - 2004. [Abstract] [Full Text] [PDF] P. J. Amrolia, G. Muccioli-Casadei, E. Yvon, H. Huls, U. Sili, E. D. Wieder, C. Bollard, J. Michalek, V. Ghetie, H. E. Heslop, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses Blood, September 15, 2003; 102(6): 2292 - 2299. [Abstract] [Full Text] [PDF] K. Matsui, L. A. O'Mara, and P. M. Allen Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy Int. Immunol., July 1, 2003; 15(7): 797 - 805. [Abstract] [Full Text] [PDF] P. Meij, J. W. J. van Esser, H. G. M. Niesters, D. van Baarle, F. Miedema, N. Blake, A. B. Rickinson, I. Leiner, E. Pamer, B. Lowenberg, et al. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease Blood, June 1, 2003; 101(11): 4290 - 4297. [Abstract] [Full Text] [PDF] L. Santodonato, G. D'Agostino, R. Nisini, S. Mariotti, D. M. Monque, M. Spada, L. Lattanzi, M. Paola Perrone, M. Andreotti, F. Belardelli, et al. Monocyte-Derived Dendritic Cells Generated After a Short-Term Culture with IFN-{alpha} and Granulocyte-Macrophage Colony-Stimulating Factor Stimulate a Potent Epstein-Barr Virus-Specific CD8+ T Cell Response J. Immunol., May 15, 2003; 170(10): 5195 - 5202. [Abstract] [Full Text] [PDF] A. Khanolkar, Z. Fu, L. J. Underwood, K. L. Bondurant, R. Rochford, and M. J. Cannon CD4+ T Cell-Induced Differentiation of EBV-Transformed Lymphoblastoid Cells Is Associated with Diminished Recognition by EBV-Specific CD8+ Cytotoxic T Cells J. Immunol., March 15, 2003; 170(6): 3187 - 3194. [Abstract] [Full Text] [PDF] S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies Blood, March 1, 2003; 101(5): 1905 - 1912. [Abstract] [Full Text] [PDF] G. Lautscham, T. Haigh, S. Mayrhofer, G. Taylor, D. Croom-Carter, A. Leese, S. Gadola, V. Cerundolo, A. Rickinson, and N. Blake Identification of a TAP-Independent, Immunoproteasome-Dependent CD8+ T-Cell Epitope in Epstein-Barr Virus Latent Membrane Protein 2 J. Virol., February 15, 2003; 77(4): 2757 - 2761. [Abstract] [Full Text] [PDF] S. Marktel, Z. Magnani, F. Ciceri, S. Cazzaniga, S. R. Riddell, C. Traversari, C. Bordignon, and C. Bonini Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation Blood, February 15, 2003; 101(4): 1290 - 1298. [Abstract] [Full Text] [PDF] P. Lang, R. Handgretinger, D. Niethammer, P. G. Schlegel, M. Schumm, J. Greil, P. Bader, C. Engel, H. Scheel-Walter, M. Eyrich, et al. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia Blood, February 15, 2003; 101(4): 1630 - 1636. [Abstract] [Full Text] [PDF] K. C.M. Straathof, C. M. Bollard, C. M. Rooney, and H. E. Heslop Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children Oncologist, February 1, 2003; 8(1): 83 - 98. [Abstract] [Full Text] [PDF] H. E. Heslop, F. K. Stevenson, and J. J. Molldrem Immunotherapy of Hematologic Malignancy Hematology, January 1, 2003; 2003(1): 331 - 349. [Abstract] [Full Text] [PDF] B. Savoldo, M. H. Huls, Z. Liu, T. Okamura, H.-D. Volk, P. Reinke, R. Sabat, N. Babel, J. F. Jones, J. Webster-Cyriaque, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection Blood, December 1, 2002; 100(12): 4059 - 4066. [Abstract] [Full Text] [PDF] M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes Science, October 25, 2002; 298(5594): 850 - 854. [Abstract] [Full Text] [PDF] P. Porcu, C. F. Eisenbeis, R. P. Pelletier, E. A. Davies, R. A. Baiocchi, S. Roychowdhury, S. Vourganti, G. J. Nuovo, W. L. Marsh, A. K. Ferketich, et al. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration Blood, September 18, 2002; 100(7): 2341 - 2348. [Abstract] [Full Text] [PDF] R. Omiya, C. Buteau, H. Kobayashi, C. V. Paya, and E. Celis Inhibition of EBV-Induced Lymphoproliferation by CD4+ T Cells Specific for an MHC Class II Promiscuous Epitope J. Immunol., August 15, 2002; 169(4): 2172 - 2179. [Abstract] [Full Text] [PDF] A. Moosmann, N. Khan, M. Cobbold, C. Zentz, H.-J. Delecluse, G. Hollweck, A. D. Hislop, N. W. Blake, D. Croom-Carter, B. Wollenberg, et al. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells Blood, August 13, 2002; 100(5): 1755 - 1764. [Abstract] [Full Text] [PDF] S. Chakrabarti, V. Mautner, H. Osman, K. E. Collingham, C. D. Fegan, P. E. Klapper, P. A. H. Moss, and D. W. Milligan Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery Blood, August 13, 2002; 100(5): 1619 - 1627. [Abstract] [Full Text] [PDF] J. W. J. van Esser, H. G. M. Niesters, B. van der Holt, E. Meijer, A. D. M. E. Osterhaus, J. W. Gratama, L. F. Verdonck, B. Lowenberg, and J. J. Cornelissen Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation Blood, May 29, 2002; 99(12): 4364 - 4369. [Abstract] [Full Text] [PDF] H. Einsele, E. Roosnek, N. Rufer, C. Sinzger, S. Riegler, J. Loffler, U. Grigoleit, A. Moris, H.-G. Rammensee, L. Kanz, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy Blood, May 13, 2002; 99(11): 3916 - 3922. [Abstract] [Full Text] [PDF] Q. Tao, J. Yang, H. Huang, L. J. Swinnen, and R. F. Ambinder Conservation of Epstein-Barr Virus Cytotoxic T-Cell Epitopes in Posttransplant Lymphomas : Implications for Immune Therapy Am. J. Pathol., May 1, 2002; 160(5): 1839 - 1845. [Abstract] [Full Text] [PDF] C. M. Bollard, C. Rossig, M. J. Calonge, M. H. Huls, H.-J. Wagner, J. Massague, M. K. Brenner, H. E. Heslop, and C. M. Rooney Adapting a transforming growth factor beta -related tumor protection strategy to enhance antitumor immunity Blood, May 1, 2002; 99(9): 3179 - 3187. [Abstract] [Full Text] [PDF] P. Comoli, M. Labirio, S. Basso, F. Baldanti, P. Grossi, M. Furione, M. Vigano, R. Fiocchi, G. Rossi, F. Ginevri, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication Blood, April 1, 2002; 99(7): 2592 - 2598. [Abstract] [Full Text] [PDF] A. C. Lankester, M. J. D. van Tol, J. M. Vossen, A. C. M. Kroes, and E. Claas Epstein-Barr virus (EBV)-DNA quantification in pediatric allogeneic stem cell recipients: prediction of EBV-associated lymphoproliferative disease Blood, April 1, 2002; 99(7): 2630 - 2631. [Full Text] [PDF] C. Rossig, C. M. Bollard, J. G. Nuchtern, C. M. Rooney, and M. K. Brenner Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy Blood, March 15, 2002; 99(6): 2009 - 2016. [Abstract] [Full Text] [PDF] Y.-J. Gan, B. I. Razzouk, T. Su, and J. W. Sixbey A Defective, Rearranged Epstein-Barr Virus Genome in EBER-Negative and EBER-Positive Hodgkin's Disease Am. J. Pathol., March 1, 2002; 160(3): 781 - 786. [Abstract] [Full Text] [PDF] G. Koehne, K. M. Smith, T. L. Ferguson, R. Y. Williams, G. Heller, E. G. Pamer, B. Dupont, and R. J. O'Reilly Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors Blood, March 1, 2002; 99(5): 1730 - 1740. [Abstract] [Full Text] [PDF] B. C. Gartner, H. Schafer, K. Marggraff, G. Eisele, M. Schafer, K. Roemer, H.-J. Laws, M. Sester, U. Sester, H. Einsele, et al. Evaluation of Use of Epstein-Barr Viral Load in Patients after Allogeneic Stem Cell Transplantation To Diagnose and Monitor Posttransplant Lymphoproliferative Disease J. Clin. Microbiol., February 1, 2002; 40(2): 351 - 358. [Abstract] [Full Text] [PDF] B. Savoldo, M. L. Cubbage, A. G. Durett, J. Goss, M. H. Huls, Z. Liu, L. Teresita, A. P. Gee, P. D. Ling, M. K. Brenner, et al. Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals J. Immunol., January 15, 2002; 168(2): 909 - 918. [Abstract] [Full Text] [PDF] V. T. Ho and R. J. Soiffer The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation Blood, December 1, 2001; 98(12): 3192 - 3204. [Full Text] [PDF] G. Gallot, R. Vivien, C. Ibisch, J. Lule, C. Davrinche, J. Gaschet, and H. Vie Purification of Ag-Specific T Lymphocytes After Direct Peripheral Blood Mononuclear Cell Stimulation Followed by CD25 Selection. I. Application to CD4+ or CD8+ Cytomegalovirus Phosphoprotein pp65 Epitope Determination J. Immunol., October 15, 2001; 167(8): 4196 - 4206. [Abstract] [Full Text] [PDF]

	Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020